Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Spinout ReadCoor Raises $27M in Series B Financing

NEW YORK – Spatial genomics startup ReadCoor announced Friday it has raised $27 million in Series B financing. 

Pavilion Capital joined as a new investor; the round also included previous investors Decheng Capital and Hansjörg Wyss. 

In a statement, the firm said it will use the proceeds to accelerate commercialization of its fluorescent in situ sequencing (FISSEQ) technology, which simultaneously captures molecular and spatial information within cells and tissues. 

"ReadCoor has made rapid progress in bringing multiomic spatial sequencing from development to the market," Victor Tong, partner at Decheng Capital and chairman of ReadCoor's board of directors, said in a statement. "The platform that ReadCoor has developed features a leading-edge technology to sequence and characterize tissue in 3D that offers the potential for new insights in clinical research and drug discovery."

ReadCoor, a spinout from George Church's lab at Harvard University's Wyss Institute for Biologically Inspired Engineering, has now raised more than $50 million. In 2016 it raised $23 million in Series A financing, led by Decheng Capital, and won a $2.5 million grant from the Bill and Melinda Gates Foundation to develop pathogen detection capabilities. In 2018, ReadCoor received a grant for an undisclosed amount from the Chan Zuckerberg Initiative to map cortical cells for the Human Cell Atlas.

The firm added that it would unveil its FISSEQ platform next month at the Advances in Genome Biology and Technology meeting.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.